Propanc Biopharma Inc., of Melbourne, Australia, said results from recent scientific experiments provide strong indicators of PRP's therapeutic potential as a clinical approach in cancer, showing a reduction of epithelial to mesenchymal transition (EMT) markers as a consequence of PRP treatment, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells. PRP, a solution for once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen, is advancing toward first-in-human studies.